Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

NextCure (NXTC) Stock Price & Analysis

357 Followers

NXTC Stock Chart & Stats

$6.23$0.25(4.18%)
At close: 4:00 PM EST
$5$6$7$8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$5.37 - $6.36
52-Week Range
$1.55 - $15.74
Previous Close
$5.98
Volume
N/A
Average Volume (3M)
65.45K
Market Cap
$27.38M
Enterprise Value
$17.87M
Total Cash (Recent Filing)
$8.73M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.36
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.79
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Modest Leverage

Modest leverage limits interest and refinancing pressure relative to a more highly indebted development-stage company. This provides some financial flexibility, although it does not offset the broader effects of ongoing losses and a shrinking equity base.

Improving Losses And Cash Burn

The narrowing net loss and improved recent burn rate indicate that management is reducing the pace of cash consumption. If sustained, this could extend the operating runway and reduce funding needs, even though the company remains unprofitable and cash flow negative.

Lower Facility Costs

Exiting the Beltsville facility removes ongoing rental commitments and consolidates the company’s physical footprint. The resulting cost reduction can support cash preservation over the next several quarters, which is strategically relevant for a company still dependent on external funding.

Bears Say

No Commercial Revenue

Without a meaningful revenue base, NextCure lacks internally generated funding to support its research programs and corporate costs. Continued operating losses also make future financial performance dependent on successful development, partnerships, or additional capital rather than established product demand.

Persistent Cash Burn

Persistent negative operating and free cash flow means the business consumes cash rather than generating it. This creates ongoing dependence on external funding to maintain operations, leaving execution and development plans vulnerable if financing is unavailable or insufficient.

Shrinking Equity Cushion

The sharp decline in stockholders’ equity reflects sustained losses and materially reduces the balance-sheet cushion available to absorb setbacks. A thinner capital base can constrain strategic flexibility and heighten financing risk while the company remains in development.

NextCure News

NXTC FAQ

What was NextCure’s price range in the past 12 months?
NextCure lowest stock price was $1.55 and its highest was $15.74 in the past 12 months.
What is NextCure’s market cap?
NextCure’s market cap is $27.38M.
When is NextCure’s upcoming earnings report date?
NextCure’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 110 days.
How were NextCure’s earnings last quarter?
NextCure released its earnings results on Nov 10, 2026. The company reported -$1.29 earnings per share for the quarter, missing the consensus estimate of -$0.9 by -$0.39.
Is NextCure overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does NextCure pay dividends?
NextCure does not currently pay dividends.
What is NextCure’s EPS estimate?
NextCure’s EPS estimate is -0.79.
How many shares outstanding does NextCure have?
NextCure has 4,579,023 shares outstanding.
What happened to NextCure’s price movement after its last earnings report?
NextCure reported an EPS of -$1.29 in its last earnings report, missing expectations of -$0.9. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NextCure?
Hedge funds hold NextCure shares: the largest hedge-fund position in NextCure is 71,885,976 shares, and hedge funds decreased their holdings by 17.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology